Chavicol is a simple allyl phenol related to better-known essential-oil phenylpropanoids such as eugenol and estragole. In the AromaForge archive it is most useful as a chemistry and aroma marker rather than as a well-supported standalone wellness active: identity, flavor-regulatory status, and biosynthetic context are stronger than constituent-specific pharmacology. The reviewed evidence supports describing chavicol as a phenolic aromatic constituent with sparse direct safety and bioactivity literature and with most public context coming from flavor or basil-pathway sources.
Chemical identity and composition
PubChem identifies chavicol as C9H10O with the IUPAC name 4-prop-2-enylphenol. It sits in a small allyl-phenol family that includes eugenol and estragole, and a biosynthesis paper in sweet basil places chavicol upstream of methylchavicol via O-methylation after reductive formation from activated p-coumaryl esters.
Aroma and practical use
- Use the recorded phenolic, medicinal, herbal, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2006 Organic & Biomolecular Chemistry study reported that chavicol biosynthesis in Thai basil proceeds through the phenylpropanoid pathway to p-coumaryl alcohol, followed by ester activation and NAD(P)H-dependent reduction to chavicol before O-methylation to methylchavicol.
This is a chemistry and pathway paper rather than a pharmacology paper, but it is the strongest direct chavicol-specific primary source located in this pass.
This experimental finding does not establish benefit, dose or safety in people using this blend.
JECFA evaluated 4-allylphenol (chavicol) as a flavouring agent and recorded no safety concern at current intake levels under the conditional assumptions of that evaluation.
This is food-flavour exposure framing, not a topical or inhalation aromatherapy-use standard.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedPubChem classifies chavicol with an irritant-style laboratory safety summary, and directly readable public fragrance-specific dermal-limit data were not located in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
JECFA lists chavicol as conditionally acceptable at current flavoring intake levels, but that conclusion is exposure-context-specific and should not be repurposed into cosmetic-use or medical claims.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
nadph_dependent_reductive_formation_in_basil
The clearest constituent-specific mechanism located here is biosynthetic rather than therapeutic: sweet basil forms chavicol through reductive elimination from activated p-coumaryl esters in an NAD(P)H-dependent step, after which chavicol can be O-methylated to methylchavicol.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No isolated chavicol human clinical studies were verified in this pass.
- Direct constituent-specific dermal sensitization, phototoxicity, or inhalation-limit literature for chavicol was not located in public sources reviewed here.
- Most bioactivity literature in this chemical family concerns eugenol, estragole, hydroxychavicol, or mixture-level oils rather than isolated chavicol itself.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.